Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -132.59% is 153% below its 5-year average of -52.31%, near the low end of its 5-year range (-132.59%–-22.64%).
76.12% below its 12-month average of -75.28%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -26.56%.
RETURN ON ASSETS (ROA)
-132.59%
RETURN ON ASSETS (ROA) AVG TTM
-75.28%
RETURN ON ASSETS (ROA) AVG 3Y
-65.73%
RETURN ON ASSETS (ROA) AVG 5Y
-52.31%
RETURN ON ASSETS (ROA) AVG 10Y
-53.85%
RETURN ON ASSETS (ROA) AVG 15Y
-45.67%
RETURN ON ASSETS (ROA) AVG 20Y
-50.07%
CURRENT VS TTM AVG
-76.12%
CURRENT VS 3Y AVG
-101.72%
CURRENT VS 5Y AVG
-153.46%
CURRENT VS 10Y AVG
-146.24%
CURRENT VS 15Y AVG
-190.30%
CURRENT VS 20Y AVG
-164.81%
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
-321.25%
vs the sector median at left
Lisata Therapeutics, Inc.
Market Cap
$10.65M
Return on Assets (ROA)
-132.59%
TTM Avg
-75.28%
3Y Avg
-65.73%
5Y Avg
-52.31%
Market Cap
$10.51M
Return on Assets (ROA)
N/A
TTM Avg
-37.02%
3Y Avg
-41.41%
5Y Avg
-41.74%
Market Cap
$10.44M
Return on Assets (ROA)
-52.23%
TTM Avg
-58.24%
3Y Avg
-82.00%
5Y Avg
-104.09%
Market Cap
$10.94M
Return on Assets (ROA)
-185.94%
TTM Avg
-166.39%
3Y Avg
-133.67%
5Y Avg
-110.62%
Market Cap
$10.96M
Return on Assets (ROA)
-404.58%
TTM Avg
-269.82%
3Y Avg
-269.82%
5Y Avg
-269.82%
Market Cap
$10.33M
Return on Assets (ROA)
-149.72%
TTM Avg
-86.94%
3Y Avg
-66.39%
5Y Avg
-60.64%
Market Cap
$10.32M
Return on Assets (ROA)
N/A
TTM Avg
-21.71%
3Y Avg
-73.35%
5Y Avg
-116.85%
Market Cap
$11.11M
Return on Assets (ROA)
-198.70%
TTM Avg
-189.50%
3Y Avg
-187.22%
5Y Avg
-200.18%
Market Cap
$11.11M
Return on Assets (ROA)
-98.26%
TTM Avg
-77.06%
3Y Avg
-65.68%
5Y Avg
-62.77%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lisata Therapeutics, Inc. (LSTA) | $10.65M | -132.59% | -75.28% | -65.73% | -52.31% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A | -37.02% | -41.41% | -41.74% |
| Satellos Bioscience Inc. (MSLE)vs › | $10.44M | -52.23% | -58.24% | -82.00% | -104.09% |
| Cerenome, Inc. (CNSY)vs › | $10.94M | -185.94% | -166.39% | -133.67% | -110.62% |
| Caring Brands, Inc. (CABR)vs › | $10.96M | -404.58% | -269.82% | -269.82% | -269.82% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.33M | -149.72% | -86.94% | -66.39% | -60.64% |
| Polyrizon Ltd. (PLRZ)vs › | $10.32M | N/A | -21.71% | -73.35% | -116.85% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.11M | -198.70% | -189.50% | -187.22% | -200.18% |
| Pluri Inc. (PLUR)vs › | $11.11M | -98.26% | -77.06% | -65.68% | -62.77% |
| BioVie Inc. (BIVI)vs › | $11.12M | -154.89% | -40.68% | -87.98% | -439.28% |
ROA
-132.6%
ROE
-177.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -93.47% |
| 2024-12-31 | -57.10% |
| 2023-12-31 | -38.10% |
| 2022-12-31 | -74.25% |
| 2021-12-31 | -28.31% |
| 2020-12-31 | -22.64% |
| 2019-12-31 | -74.03% |
| 2018-12-31 | -36.27% |
| 2017-12-31 | 36.26% |
| 2016-12-31 | -63.00% |
| 2015-12-31 | -141.40% |
| 2014-12-31 | -43.46% |
| 2013-12-31 | -43.40% |
| 2012-12-31 | -100.69% |
| 2011-12-31 | -30.34% |
| 2010-12-31 | -16.30% |
| 2009-12-31 | -24.68% |
| 2008-12-31 | -506.60% |
| 2007-12-31 | -276.69% |
| 2006-12-31 | -506.37% |
| 2005-12-31 | -271.52% |
| 2004-12-31 | -1758.15% |
| 2003-12-31 | -335.00% |
| 2002-12-31 | -98.03% |
| 2001-12-31 | -110.71% |
| 2000-12-31 | -43.89% |
| 1999-12-31 | -21.51% |
| 1998-12-31 | 0.00% |
| 1998-03-31 | -2232.80% |
| 1996-03-31 | 1256.23% |
